These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19953882)

  • 1. [Comparison of single-agent docetaxel versus docetaxel plus platinum combination agent in second-line treatment for advanced non-small cell lung cancer].
    Zhang YF; Yu YF; Lu S
    Zhonghua Yi Xue Za Zhi; 2009 Jun; 89(22):1544-8. PubMed ID: 19953882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and prognostic factors of 178 advanced non-small lung cancer patients undergoing different second-line chemotherapeutic regimens].
    Kong Q; Wang XY; Jiang RC; Ba Y; Li K
    Zhonghua Zhong Liu Za Zhi; 2016 Apr; 38(4):294-9. PubMed ID: 27087377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
    Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long progression-free survival with first-line paclitaxel plus platinum is associated with improved response and progression-free survival with second-line docetaxel in advanced non-small-cell lung cancer.
    Macedo-Pérez EO; Morales-Oyarvide V; Mendoza-García VO; Dorantes-Gallareta Y; Flores-Estrada D; Arrieta O
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):681-90. PubMed ID: 25059320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
    Ng R; Loreto M; Lee R; Leighl NB
    Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
    Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
    Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
    Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
    Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
    Gebbia V; Gridelli C; Verusio C; Frontini L; Aitini E; Daniele B; Gamucci T; Mancuso G; Di Maio M; Gallo C; Perrone F; Morabito A
    Lung Cancer; 2009 Feb; 63(2):251-8. PubMed ID: 18632181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer].
    Gu LP; Shen SP; Chen ZW
    Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):939-42. PubMed ID: 21223805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
    Belvedere O; Follador A; Rossetto C; Merlo V; Defferrari C; Sibau AM; Aita M; Dal Bello MG; Meduri S; Gaiardo M; Fasola G; Grossi F
    Eur J Cancer; 2011 Jul; 47(11):1653-9. PubMed ID: 21514147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacies and toxicities of different platinum-based combination chemotherapies for patients with advanced non-small cell lung cancer].
    Liu J; Ji F; Li J; Wang B; Wu G
    Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(8):580-3. PubMed ID: 24762685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy.
    Krzakowski M; Ramlau R; Jassem J; Szczesna A; Zatloukal P; Von Pawel J; Sun X; Bennouna J; Santoro A; Biesma B; Delgado FM; Salhi Y; Vaissiere N; Hansen O; Tan EH; Quoix E; Garrido P; Douillard JY
    J Clin Oncol; 2010 May; 28(13):2167-73. PubMed ID: 20351334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
    Yi Y; Liu Z; Fang L; Li J; Liu W; Wang F; Fu P; Xie C; Liu J; Song B
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):65-74. PubMed ID: 32533335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
    Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
    Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent chemotherapy compared with combination chemotherapy as second-line treatment in extensive-stage small cell lung cancer: a retrospective analysis.
    Song Z; Shao L; Lin B; Zhang Y
    Clin Transl Oncol; 2013 Oct; 15(10):843-8. PubMed ID: 23423808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.